Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)
This study is ongoing, but not recruiting participants.
First Posted: September 10, 2009
Last Update Posted: March 19, 2014
Astellas Pharma Inc
Information provided by (Responsible Party):